Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024154 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00024154: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00024154 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 132 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024154, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving trastuzumab together with gefitinib works in treating patients with HER2-positive breast cancer. The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as gefitinib may also interfere with the growth of tumor cells and may enhance the effects of trastuzumab. Combining trastuzumab with gefitinib may be an effective treatment for metastatic breast cancers with high amounts of HER2
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL trastuzumab
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024154
The ClinicalTrials.gov registry entry for NCT00024154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00024154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024154 about?
NCT00024154 is a clinical study titled "Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer". This phase II trial is studying how well giving trastuzumab together with gefitinib works in treating patients with HER2-positive breast cancer. The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances...
What is the current status of trial NCT00024154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2002-02.
What interventions are being tested in trial NCT00024154?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trastuzumab (BIOLOGICAL), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00024154?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.